Skip to main content

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2339${count})

  • Therapeutic Pipeline Program, 2019
    Study of a Levodopa Adjunctive Therapeutic without Dyskinesia Liability

    Study Rationale:
    Evidence suggests that levodopa’s efficacy and side effects (uncontrolled movements called dyskinesia) are caused by activating dopamine D1 receptors. An optimal Parkinson’s disease...

  • Astrocyte Biology in Parkinson's Disease, 2019
    Control of Astrocyte Function by LRRK2

    Study Rationale:
    Mutations in the LRRK2 gene are known to cause Parkinson’s disease (PD), but how mutations in this gene lead to neuron death is not yet known. Astrocytes, which are brain cells that s...

  • Astrocyte Biology in Parkinson's Disease, 2019
    How Astrocytes Cause Neuronal Loss by Reacting to Alpha-synuclein

    Study Rationale:
    Research in Parkinson’s disease has largely focused on events that occur within neurons that are lost in disease. However far more abundant than neurons in the human brain are a type...

  • Astrocyte Biology in Parkinson's Disease, 2019
    Exploring Proteins associated with Alpha-synuclein in Astrocytes at Different Stages of Parkinson’s Disease

    Study Rationale:
    In addition to neurons, astrocytes are the other major cell type that have increased alpha-synuclein in Parkinson’s disease (PD). In fact, more astrocytes have increased alpha...

  • Improved Biomarkers and Clinical Outcome Measures, 2019
    Mitochondrial Complex 1 PET Imaging in Parkinson’s Disease

    Study Rationale:
    Methods are needed for imaging early pathological changes in the brain. With such brain imaging, we would be able to determine whether medications are protecting against progression...

  • Improved Biomarkers and Clinical Outcome Measures, 2019
    Development of a Colony Stimulating Factor 1 Receptor (CSF1R) Radioligand for Imaging Microglia-selective Inflammation

    Study Rationale:
    We have shown that Parkinson’s disease has an underlying neuroinflammatory component that involves microglia, which are inflammatory and immune cells in the brain. We have developed...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.